DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Status of Application /Claims/Election Applicant’s election without traverse of Group I (Claims 1 -14 ) in the reply filed on 3/11/2026 is acknowledged. Claims 1 -24 are pending. Claims 1 5-24 are currently withdrawn from further consideration pursuant to 37 CFR 1.142 (b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 1-14 are the subject of the present Official action . Priority Applicant’s claim for the benefit of a prior-filed application PRO 63/195,361 and 371 pf PCT/US2022/031528 filed on 6/1/2021 and 5/31/2022, respectively, under 35 U.S.C 119(e) or under 35 U.S.C 120, 121 or 365(c) is acknowledged. Accordingly, the effective priority date of the instant application is granted as 6/1/2021. Information Disclosure Statement The information disclosure statements (IDS) submitted on 12/4/2023 were received. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement was considered by the examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-9 and 12-14 is rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Yang et al. US 2020/0404891, published 12/31/2020, priority date 4/20/2017 (hereinafter Yang) as evidenced by Denner et al. "Genetic alterations of the long terminal repeat of an ecotropic porcine endogenous retrovirus during passage in human cells." Virology 314.1 (2003): 125-133 (hereinafter Denner ). Claim 1: Yang describes a method for generating multiplexed genetically modified animals like porcine endogenous retrovirus (PERV) inactivated pigs which can be used as a tissue source for xenotransplantation into non-porcine animals like humans (Yang, abstract). Yang describes a persistent problem wherein PERV elements, which are integrated into the genome of all pigs, pose a risk of zoonotic infection during xenotransplantation, which potentially causes immunodeficiencies and tumors (Yang, para 2-6). Yang describes the use of a Cas9 nickase protein and a gRNA which has sequence complementarity to a target site overlapping or proximate to a PERV target site, which leads to the deletion and knockout of PERV genes at multiple sites within the pig genome (Yang, para 16, 144, 167 and example 12). Denner is provided as evidentiary support showing that the number of repeats in human-adapted PERV carrying a LTR specific for PERV-C correlates with expression ( Denner , pg 130 col 1). Yang conduced numerous experiments to achieve PERV knockout (deletion) in fibroblast cell lines, achieving <50% knockout efficiency when multiple gRNAs were used (Yang, example 12). Claim 2: Yang describes repeat procedures to increase targeting efficiency by conducting multiple rounds of editing and using multiple gRNAs (Yang, para 187 and example 12). Claim 3: Yang describes the targeted deletion of repeat PERV elements, particularly within the LTRs, resulting in the elimination of activity of PERV elements (Yang, para 206 and claim 2). Claims 4-6: Yang describes targeting PERV elements which are porcine endogenous retrovirus that are pathogenic to humans (Yang, para 1-3 and claims 1 and 4). Claims 7-9 and 12-13: Yang describes preferred embodiments wherein the genomic DNA is from a cancer cell, human cancer cell or porcine genomic DN A (Yang, para 83-85). Claim 14: Yang describes avoiding cellular damage and mutations during in vivo modifications (Yang, para 196). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-14 are rejected under 35 U.S.C. 103 as being unpatentable over Yang ( supra ) in view of Denner ( supra ). A description of Yang can be found above with respect to claims 1-9 and 12-14. Yang does not describe modifications in a T cell or human T cell. Claims 10-11: Denner describes infecting C8166 human T cell lines with PERV/5 ( Denner , pg 128 col 2 and Fig 5). It would have been obvious to one of ordinary skill in the art to apply the methods of Yang to target PERV elements found in T cells as described by Denner . It would have been a matter of combining prior art elements according to known methods to yield predictable results since T cell mediated rejection is a major barrier to pig-to-human xenotransplantation. T hus, on e of ordinary skill would have motivation to target T cells in order to prevent the transmission of infectious viruses to human recipients, thus minimizing long-term zoonotic infection threats. One would have a reasonable expectation of success given that the gRNA could readily be modified and programmed to target latent PERV elements in T cells Accordingly, in the absence of evidence to the contrary, one of ordinary skill in the art would have considered the claimed invention to have been prima facie obvious to at the time the invention was made. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT Dr. ALEXANDER NICOL whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-6383 . The examiner can normally be reached on FILLIN "Work Schedule?" \* MERGEFORMAT M-F 8-5 EST . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached on FILLIN "SPE Phone?" \* MERGEFORMAT (571)272-1085 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Alexander Nicol Patent Examiner Art Unit 1633 /ALEXANDER W NICOL/ Examiner, Art Unit 1634